

PTO/S8086 (08-03)
Approved for use through DSR02006, ONE 0691-0031
U.S. Parent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to ecolored to a collection of information unless it displays a wall OMB control custom

Substitute for form 14499/27O

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 1

| Complete If Known      |                 |  |
|------------------------|-----------------|--|
| Application Number     | 09/430,966      |  |
| Filing Date            | 11/01/1999      |  |
| First Nemed Inventor   | Bart DE CORTE   |  |
| Group Art Unit         | 1624            |  |
| Examiner Name          | VENKATARAMAN    |  |
|                        | BALASUBRAMANIAN |  |
| Attorney Docket Number | JAB 1425        |  |

|            |  | OTHER - NON PATENT LITERATURE DOCUMENTS  |                                       |            |
|------------|--|--|---------------------------------------|------------|
| Examiner's | Cite<br>No.1                                     | include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the them (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), waternal-base number(s), publisher, city antifor country where published | Translation                           | Τ°         |
| ivis       |  | VINGERHOETS, Antiviral activity TMC 125 SDM, CROI, San Francisco, Feb. 2004  | No                                    |            |
| m          |  | ARNOLD, Conformational Flexibility of DAPYs: activity against resistant HIV, Aug. 2003   | No .                                  |            |
| h          | l —  | VINGERHOETS, Resistance before/after therapy - TMC 125C207, XII Resistance Mexico, June 2003   | No                                    |            |
| (M)        |  | VINGERHOETS, Resistance profile clinical isolates TMC 125, XII Resistance Mexico, June 2003  | No .                                  |            |
| M          |  | GAZZARD, TMC 125 C207 study treatment-experienced, CROI Seattle, Feb. 2002   | No                                    |            |
| 1/0        |  | LANGE, TMC 125 decay rate vs ERA, CROI Seattle, Feb., 2002   | Nto                                   | 1          |
| W          |  | GAZZARD, 7 day treatment-experienced, WAC Bercelone, Jul. 2002   | No                                    |            |
| W          |  | LEWI, Potency & multiple binding modes of TMC 125, CROI Boston, Feb. 2003  | No                                    | 1          |
| 1/1        | <del> </del>                                     | M-P de BETHUNE, TMC 125 resistance profiles, Resistance, Mexico, June 2003   | No                                    | 1          |
| M          |  | VINGERHOETS, TMC 126-C207 resistance analysis, Resistance, Mexico, June 2003   | No                                    |            |
| N          |  | TMC 125 for 7 days in HIV-1+ individuals with NNRTI resistance (TMC 125-<br>C207), AIDS, 17(18): F49-54, Dec. 5, 2003  | No                                    |            |
| W          |  | TMC 125 as 7d monotherapy in ARV-naive subjects (TMC 125-C208), AIDS, 17(17); 2487-2494, Nov. 21, 2003   | No                                    |            |
| M          |  | TMC 125 similar potency to 5-thug, 3-class regimen, AIDS, 17(16): 2623-2627Dec. 5, 2003  | No                                    | _=         |
| m          |  | LIDIER BLAGOVIC, Velidation of a model for the complex of HIV-1 reverse transcriptase with normucleoside inhibitor TMC125, Journal of American Chemical Society, 2003, 125(20), pp.6016-6017   | No                                    |            |
| W)         |  | GULICK, New Antiretroviral drugs, Clinical Microbiology and Infection, 2003, 9(3), pp. 186-193   | No                                    |            |
| h          |  | LUDOVICI, Evolution of enti-HIV drug candidates. Part 3: diarytpyrimidine, (DAPY)anatogues.Bioorganic-8: Medicinal Chemstry Letters (2001), 11(17), pp. 2235-2239.   | No                                    | -          |
|            |  |  |                                       | 7          |
|            |  |  |                                       |            |
|            |  |  |                                       | <b>├</b> ─ |
|            |  |  | · · · · · · · · · · · · · · · · · · · | +          |
|            | <del>                                     </del> |  |                                       |            |
|            |  |  |                                       |            |
|            |  |  | <b> </b>                              | $\vdash$   |
|            |  |  | <del></del>                           | +-         |
|            | ├  |  | -                                     | +-         |

| Examiner<br>Stansture | V. Belesuraman | Date<br>Considered | 4127104 |
|-----------------------|----------------|--------------------|---------|

Sometime | V | Acceptable | T | C | C | C |

EXAMINET: Initial if reference considered, whether or not challon is in conformance with IMPEP 805. Date line through claston if not in conformance and not considered. Include copy of this form with need consemunication to applicant. Applicants unique claston designation number (optional), "See Kinds Codes or USPITO Patent Documents at <a href="https://www.uspro.com/">www.uspro.com/</a>, or IMPEP 901.04. \* Briter Office that liseued the document, by the two-letter code (MMPO Standard \$7.5). \* Por Japanose petent documents, the indication of the year of the reign of the Emperor must precede the serial number of the petent document. \* Kind of document by the appropriate symbols as indicated on the document under WEPO Standard \$7. 16 if postable. \* Applicant is to place a check mark here if English tanguage Transtition is attached.